Free Trial

Protagonist Therapeutics (PTGX) Competitors

Protagonist Therapeutics logo
$75.73 -1.95 (-2.51%)
Closing price 10/16/2025 04:00 PM Eastern
Extended Trading
$75.68 -0.05 (-0.06%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PTGX vs. GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, and ELAN

Should you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), Qiagen (QGEN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

Protagonist Therapeutics vs. Its Competitors

Genmab A/S (NASDAQ:GMAB) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Genmab A/S has a net margin of 37.53% compared to Protagonist Therapeutics' net margin of 24.88%. Genmab A/S's return on equity of 21.03% beat Protagonist Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S37.53% 21.03% 16.98%
Protagonist Therapeutics 24.88%8.12%7.41%

Genmab A/S presently has a consensus price target of $40.80, suggesting a potential upside of 24.58%. Protagonist Therapeutics has a consensus price target of $72.00, suggesting a potential downside of 4.93%. Given Genmab A/S's higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.82
Protagonist Therapeutics
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.83

Genmab A/S has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.2, indicating that its share price is 120% more volatile than the S&P 500.

In the previous week, Genmab A/S had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 28 mentions for Genmab A/S and 22 mentions for Protagonist Therapeutics. Genmab A/S's average media sentiment score of 0.66 beat Protagonist Therapeutics' score of 0.48 indicating that Genmab A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
8 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Protagonist Therapeutics
7 Very Positive mention(s)
3 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Protagonist Therapeutics. Genmab A/S is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.12B6.73$1.14B$1.9916.46
Protagonist Therapeutics$434.43M10.84$275.19M$0.70108.19

Summary

Genmab A/S beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Protagonist Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PTGX vs. The Competition

MetricProtagonist TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.83B$3.41B$6.08B$10.55B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio108.1923.0784.6627.19
Price / Sales10.84486.15608.04132.91
Price / Cash17.2046.9737.8662.13
Price / Book6.6810.5012.386.65
Net Income$275.19M-$52.47M$3.32B$276.79M
7 Day Performance-12.95%2.90%2.25%1.75%
1 Month Performance27.88%15.36%9.63%5.15%
1 Year Performance61.06%14.29%73.84%36.96%

Protagonist Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PTGX
Protagonist Therapeutics
1.7685 of 5 stars
$75.73
-2.5%
$72.00
-4.9%
+61.2%$4.83B$434.43M108.19120Analyst Forecast
Insider Trade
GMAB
Genmab A/S
3.7565 of 5 stars
$31.81
-0.1%
$40.80
+28.3%
+44.9%$20.42B$3.26B15.982,682Trending News
Analyst Forecast
Short Interest ↑
Analyst Revision
SMMT
Summit Therapeutics
3.0162 of 5 stars
$21.35
-5.7%
$31.29
+46.5%
-6.4%$15.86B$700K-21.14110Upcoming Earnings
ASND
Ascendis Pharma A/S
2.8766 of 5 stars
$209.55
-2.4%
$244.64
+16.7%
+58.9%$12.93B$393.54M-40.611,017News Coverage
Analyst Revision
Gap Up
RDY
Dr. Reddy's Laboratories
3.1513 of 5 stars
$14.34
+1.2%
$16.95
+18.2%
-10.1%$11.97B$3.81B21.7327,811Positive News
VTRS
Viatris
3.1067 of 5 stars
$9.74
-2.5%
$10.40
+6.8%
-14.6%$11.36B$14.12B-3.3632,000News Coverage
Analyst Forecast
ROIV
Roivant Sciences
3.0735 of 5 stars
$16.04
-0.5%
$19.94
+24.3%
+42.9%$10.95B$29.05M-22.91860Insider Trade
BBIO
BridgeBio Pharma
4.494 of 5 stars
$55.49
+1.3%
$63.94
+15.2%
+108.9%$10.61B$235.81M-13.57400Positive News
Analyst Revision
MRNA
Moderna
4.2459 of 5 stars
$26.83
-2.5%
$41.81
+55.8%
-52.8%$10.48B$3.06B-3.565,800Analyst Revision
QGEN
Qiagen
4.1288 of 5 stars
$46.93
flat
$49.40
+5.3%
+14.5%$10.43B$2.04B27.735,765
ELAN
Elanco Animal Health
2.5478 of 5 stars
$19.77
-1.5%
$19.14
-3.2%
+54.6%$9.82B$4.48B22.999,000Analyst Revision

Related Companies and Tools


This page (NASDAQ:PTGX) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners